Infusion with paracetamol

ApprovedSmall molecule

Infusion with paracetamol is one of 7 small molecule programs targeting Bacterial Meningitis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bacterial MeningitisActive, not recruiting

Bacterial MeningitisApproved

Active, not recruiting

Competition

Competitive Landscape

11 competitors in Bacterial Meningitis

#DrugCompanyPhaseTrials

Tylenol

KKenvue Brands

Approved

—2

Avycaz

PPhiladelphia Eye Associates

Approved

—3

Merrem

BB. Braun Medical Inc.

Paracetamol

1 5

Infusion with paracetamol

UUniversity of Helsinki

Approved

1 6

Glycerol

NNova Scotia Health Authority

Phase 3

1 7

Cubicin

BBaxter Healthcare Corporation

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Bacterial Meningitis1 trial

Slow Initial β-lactam Infusion With High-dose Paracetamol to Improve the Outcomes of Childhood Bacterial Meningitis

Completed·UUniversity of Helsinki·Phase 4·NCT01540838·375 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Infusion with paracetamol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Infusion with paracetamol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Infusion with paracetamol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Helsinki company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UUniversity of Helsinki

Infusion with paracetamol

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Bacterial Meningitis1 trial

References

Drug Info

Quick Facts

Related News